Recent advances of benzimidazole as anticancer agents
Chemical Biology & Drug Design · 2023-08 · 102 (2) · 357-376
DOI: 10.1111/cbdd.14236 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 03.04.2023. Verfasst von Sneha Venugopal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Pharmacy, Lovely Professional University, Punjab, India. Hauptthemen laut MEDLINE: Antineoplastic Agents. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 91 Literaturangaben.
Abstract (Originalsprache)
Cancer is the second leading cause of death globally, with 9.6 million deaths yearly. As a life‐threatening disease, it necessitates the emergence of new therapies. Resistance to current chemotherapies drives scientists to develop new medications that will eventually be accessible. Because heterocycles are so common in biological substances, compounds play a big part in the variety of medications that have been developed. The “Master Key” is the benzimidazole nucleus, which consists of a six‐membered benzene ring fused with a five‐membered imidazole/imidazoline ring, which is an azapyrrole. One of the five‐membered aromatic nitrogen heterocycles identified in American therapies that have been approved by the Food and Drug Administration (FDA). Our results show that benzimidazole's broad therapeutic spectrum is due to its structural isosteres with purine, which improves hydrogen bonding, electrostatic interactions with topoisomerase complexes, intercalation with DNA, and other functions. It also enhances protein and nucleic acid inhibition, tubulin microtubule degeneration, apoptosis, DNA fragmentation, and other functions. Additionally, readers for designing the more recent benzimidazole analogues as prospective cancer treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, School of Pharmacy, Lovely Professional University, Punjab, India.
Zitieren
APA
Venugopal, S., Kaur, B., Verma, A., Wadhwa, P., Magan, M., Hudda, S., & Kakoty, V. (2023). Recent advances of benzimidazole as anticancer agents. Chemical Biology & Drug Design, 102(2), 357-376. https://doi.org/10.1111/cbdd.14236
Vancouver
Venugopal S, Kaur B, Verma A, Wadhwa P, Magan M, Hudda S, et al. Recent advances of benzimidazole as anticancer agents. Chemical Biology & Drug Design. 2023;102(2):357-376. doi:10.1111/cbdd.14236
BibTeX
@article{Venugopal2023,
author = {Venugopal, Sneha and Kaur, Balwinder and Verma, Anil and Wadhwa, Pankaj and Magan, Muskan and Hudda, Sharwan and Kakoty, Violina},
title = {Recent advances of benzimidazole as anticancer agents},
journal = {Chemical Biology & Drug Design},
year = {2023},
volume = {102},
number = {2},
pages = {357--376},
doi = {10.1111/cbdd.14236}
}
EUVIMED